ONC
Premium GrowerBeOne Medicines AG · Healthcare · Switzerland · $43.0B cap · $182.8M/day traded
$415.96 -1.0% · close 12 Nov · scored 13 Nov
Premium Grower: Strong business with the market behind it, priced at a premium.
Around its 5 Nov results, analysts raised next year's EPS estimate 5.5%.
As of 13 Nov 2026, the MoatMap Score for BeOne Medicines AG (ONC) is 89/100, ranked against 25,000+ stocks in 38 markets (Quality 82, Value 23, Momentum 85, each scored against its sector).
Does the score work? Each tenth of the ranking, tracked monthly. See the record →
ABOUT BEONE MEDICINES AG
Read
BeOne Medicines AG, while not publicly traded under the provided ticker and country combination, is likely a pharmaceutical or biotechnology company focused on developing novel medical treatments. Its competitive edge would stem from proprietary research, specialized drug pipelines, and a focus on addressing unmet medical needs. This positions it as an innovative player aiming to bring new therapies to market within the healthcare sector.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 1.4B | 2.5B | 3.8B | 5.3B | 55.7% | 6.6B | 6.8B | 7.8B | 21.1% |
| EPS | -15.73 | -276.80 | -120.62 | -89.16 | 39.48 | — | 7.80 | 9.99 | 11.02 | -47.2% |
| Shares | — | 94.9M | 94.9M | 94.9M | 94.9M | 0.0% | 105.4M | — | — | — |
| Debt | — | 596.7M | 930.2M | 1.1B | 1.1B | 22.4% | 2.1B | — | — | — |
| Equity | — | 4.4B | 3.5B | 3.3B | 4.4B | -0.2% | — | — | — | — |
| Op CF | — | -1.5B | -1.2B | -140.6M | 1.1B | — | 1.6B | — | — | — |
| Inv CF | — | 1.1B | 60.0M | -548.4M | -276.2M | — | — | — | — | — |
| Fin CF | — | -19.0M | 416.5M | 193.4M | 1.1B | — | — | — | — | — |
Above its 200-day average and 2% below its 52-week high.
Calmer than 62% of stocks we rank over the past year (volatility 36% a year).
How this is worked out
The Price check reads only the chart, the price side of the Momentum score in words; it is not the MoatMap Score.
- Still falling: It set a new 52-week low in the last two weeks, after a deep fall.
- Finding a floor: It fell hard, but has set no new low for more than two weeks.
- Turning up: It has climbed off its low and is back above a rising 50-day average.
- In an uptrend (this stock): It is near its 52-week high and above its 200-day average.
- No clear trend: None of the above: no recent deep fall and no steady climb.
- No read yet: Not enough price history yet: it needs a year of trading.
In past US falls, waiting for Turning up cut the chance of another 20% drop from 42% to 33%. Returns were no better, and 33% of turns failed.
The exact rules
Still falling is a new 52-week low in the last two weeks, at least 25% below the high, with the low set after the high. Finding a floor is the same fall with no new low in the last two weeks. Turning up is 20 or more trading days without a new low, at least 10% off it, and back above a rising 50-day average. In an uptrend is above the 200-day average, with the 50-day average above the 200-day, and within 15% of the high. No clear trend is everything else. No read yet is under 252 trading days of history, or missing data. A new state shows once it has held for three trading days.
In 2,112 US drawdowns since 2001, buying while the price was still falling was followed by a further 20% drop 42% of the time. Waiting for a turn (the Turning up rule above) cut that to 33%, at about 7% higher prices and with no better returns. Part of that cut is simply not buying: 13% of falls never turned, and waiting kept those out. Among turns that were bought, 38% still fell another 20%, and 33% of turns were followed by a new low within six months. The benefit was largest in crashes such as 2008 and 2020.
What it measures: how much the price moved day to day over the past year, scaled to a yearly figure (annualised volatility) and ranked against every stock we cover. Very calm under 20% a year, Calm 20 to 30%, Average 30 to 40%, Bumpy 40 to 55%, Very bumpy above that.
What we found: across about 13,500 stocks in 34 markets (2002 to 2025), past swings were a good guide to the next year's, and bumpier stocks fell further. How much further changed too much between eras to put a number on it.
Calm is not safe: a calm stock can still slide steadily.
Rules fixed before any data was fetched. Describes the chart, not a recommendation.
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ONC are excluded.
| Ticker | Company | Mkt Cap | Score |
|---|---|---|---|
| ONC | BeOne Medicines AG(you) | $43.0B | 89 |
| BANB.SW | Bachem Holding AG | $7.5B | 50 |
| BSLN.SW | Basilea Pharmaceutica AG | $1.0B | 97 |
| SOON.SW | Sonova Holding AG | $20.4B | 84 |
| CRSP | CRISPR Therapeutics AG | $4.8B | 11 |
| MTD | Mettler-Toledo International Inc. | $33.5B | 71 |
| STMN.SW | Straumann Holding AG | $19.1B | 78 |
| LONN.SW | Lonza Group AG | $53.5B | 65 |
| PHVS | Pharvaris N.V. | $2.2B | 19 |
| SDZ.SW | Sandoz Group AG | $42.4B | 56 |
Peer medians: ROE 7.2% · P/E 31.9x · Gross margin 57.2%
Company Deep Dive
A 10,000-word report: the business and its segments, what management promised on earnings calls and whether it delivered, the competition, and how things could turn out.